A previous study reported that, after epithelial-mesenchymal transition, breast cancer cells can be terminally differentiated into adipocytes when co-treated with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (rosiglitazone) and mitogen-activated protein kinase kinase (MEK) inhibitor (trametinib) [31]. Here, MAP2K7 is linked to breast cancer.